Mini-Sentinel: Summary of Antidiabetic Agent Use During Pregnancy

Basic Details
Date Posted
Thursday, January 2, 2020
Medical Product
alpha-glucosidase inhibitor
amylin analog
dipeptidyl peptidase-4 (DPP-4) inhibitor
glucagon-like peptide-1 (GLP-1) receptor agonist
injectable insulin
meglitinide analog
Health Outcome(s)
exposure in pregnancy

This report contains estimates of the prevalence of antidiabetic agent use among femalesĀ 10 to 54 years of age who delivered a live-born infant between January 1, 2001 and December 31, 2013 in the Mini-Sentinel Distributed Database (MSDD). Results for antidiabetic agent use are also presented for a matched comparator cohort with no live-birth deliveries during the request period.

Data from January 1, 2001 to December 31, 2013, from 15 Data Partners contributing to the MSDD were included in this report. This request was distributed to Data Partners on May 14, 2015.

Additional Details
FDA Center
Time Period
January 1, 2001 - December 31, 2013
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
Females 10 to 54 years of age
Data Sources
Mini-Sentinel Distributed Database (MSDD)